Merck & Co Expands C Diff Franchise With US Zinplava Approval
Executive Summary
Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.
You may also be interested in...
Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
The latest drug development news and highlights from our US FDA Performance Tracker.
Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development
Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.